Sideroflexin-3 (SFXN3)

Sideroflexin-3 (SFXN3) is an inner mitochondrial membrane protein belonging to the sideroflexin family of mitochondrial carriers, which includes SFXN1-5[4][2]. SFXN3 is primarily expressed in neuronal synaptic terminals and has been shown to localize to the inner mitochondrial membrane via the carrier import pathway, dependent on the mitochondrial inner membrane potential[4][2]. Unlike some related sideroflexins, SFXN3 does not appear to be essential for canonical bioenergetic pathways or mitochondrial respiration, but it is implicated in the regulation of neurodegeneration pathways, influencing proteins and pathways such as CSPα and Caspase-3, which are associated with synaptic stability, cell death, and neurodegenerative diseases including Parkinson’s and Alzheimer’s[1][4].\nExperimental manipulation of SFXN3 levels alters synaptic morphology and its overexpression provides neuroprotective effects in Drosophila models of Parkinson’s disease, although loss of SFXN3 is not sufficient to induce neurodegeneration in mice[1][4]. Structurally, SFXN3 is predicted to be a largely helical protein with 4 transmembrane domains and regions implicated in mitochondrial targeting and chaperone interaction[2][3]. The broader SFXN family is involved in mitochondrial iron homeostasis, amino acid transport, redox balance, and possibly one-carbon metabolism[6][5], but human SFXN3 is specifically linked to synaptic and neuronal mitochondrial function, with a suggested but not yet fully established therapeutic potential for modulating neurodegenerative disease progression[4].\nNo direct drug interactions, mechanisms of drug action, biomarkers, or specific safety concerns have been reported for SFXN3 as of the current literature[4][5][6].

Other names

SFXN3SFX3SLC56A3BA108L7.2sideroflexin-3